These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 7826406)

  • 1. [Synthesis and comparative analysis of antigenic activity of peptides from hypervariable region V3 of human immunodeficiency virus I gp120 surface glycoprotein].
    Semiletov IuA; Rzhaninova AA; Garaev MM
    Bioorg Khim; 1994 Oct; 20(10):1070-9. PubMed ID: 7826406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
    Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
    J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of synthetic peptides for the detection of antibodies against human immunodeficiency virus].
    Lottersberger J; Salvetti JL; Tonarelli G
    Rev Argent Microbiol; 2003; 35(3):149-55. PubMed ID: 14587377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An enzyme-linked immunosorbent assay determining anti-principal neutralizing determinant antibodies using synthetic peptides deduced from cDNA sequences of HIV-1 V3 loop domain].
    Ishimoto S; Fujimura Y; Yamanaka T; Shimoyama T; Nishida S; Matsuoka H; Nishikawa K; Yoshioka A; Narita N; Honda M
    Rinsho Ketsueki; 1995 Mar; 36(3):193-9. PubMed ID: 7540222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
    Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O
    J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combinatorial peptide library around variation of the human immunodeficiency virus (HIV-1) V3 domain leads to distinct T helper cell responses.
    Estaquier J; Boutillon C; Georges B; Ameisen JC; Tartar A; Auriault C
    J Pept Sci; 1996; 2(3):165-75. PubMed ID: 9231325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
    Neurath AR; Strick N; Debnath AK
    J Mol Recognit; 1995; 8(6):345-57. PubMed ID: 9052975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of diagnostic efficiency of the recombinant protein modeling immunodominant epitope V3 of envelope gp120 for immunoenzyme detection for HIV-1 infection antibodies].
    Riabinina SA; Baranova EN; Sharipova IN; Susekina MI; Puzyrev VF; Obriadina AP; Burkov AN; Ulanova TI
    Mol Gen Mikrobiol Virusol; 2007; (3):33-6. PubMed ID: 17886471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing of novel antigenic peptide cocktail for the detection of antibodies to HIV-1/2 by ELISA.
    Tiwari RP; Jain A; Khan Z; Kumar P; Bhrigu V; Bisen PS
    J Immunol Methods; 2013 Jan; 387(1-2):157-66. PubMed ID: 23098841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody reactivity to synthetic peptides representing the principal neutralizing determinant of HIV-1 in mouse strains following repeated immunization with recombinant gp160.
    Warren RQ; Wolf H; Stunz GW; Kennedy RC
    Exp Clin Immunogenet; 1993; 10(3):168-75. PubMed ID: 8286127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
    Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
    J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
    Zvi A; Feigelson DJ; Hayek Y; Anglister J
    Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression, purification, and isotope labeling of a gp120 V3 peptide and production of a Fab from a HIV-1 neutralizing antibody for NMR studies.
    Sharon M; Görlach M; Levy R; Hayek Y; Anglister J
    Protein Expr Purif; 2002 Apr; 24(3):374-83. PubMed ID: 11922753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.
    Vu HM; de Lorimier R; Moody MA; Haynes BF; Spicer LD
    Biochemistry; 1996 Apr; 35(16):5158-65. PubMed ID: 8611499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.